Frontiers in Cardiovascular Medicine
JUNE 28, 2024
Septic cardiomyopathy, a life-threatening complication of sepsis, can cause acute heart failure and carry a high mortality risk. These exosomes can both diagnose and treat septic cardiomyopathy, playing a crucial role in its development and progression. Current treatments have limitations.
DAIC
MARCH 6, 2024
Food and Drug Administration’s ( FDA ) Breakthrough Device Designation for their ECGvision-TTR Technology for early detection of ATTR-Cardiomyopathy. Food and Drug Administration’s (FDA) Breakthrough Devices Program , which provides patients with timely access to innovative medical devices.
Frontiers in Cardiovascular Medicine
JULY 11, 2024
BackgroundDilated cardiomyopathy (DCM) is a heterogeneous myocardial disorder with diverse genetic or acquired origins. Notable advances have been achieved in discovering and understanding the genetics of DCM.
DAIC
APRIL 3, 2024
This leap in early detection marks both a significant medical innovation and a new era in the detection of cardiovascular disease. specificity, underscoring its significant potential to assist in the detection and appropriate management of cardiomyopathy in pregnant women, reducing associated disease burden and risk of death.5
Dr. S. Venkatesan MD
JULY 1, 2024
In simple terms it mimics a heart of Hypertrophic cardiomyopathy, which we know has brisk ejection. We can also understand the principles of the management of cardiomyopathy from a Giraffe’s heart. This forms the basis behind the ventricular reduction and reconstruction surgery for Ischemic dilated cardiomyopathy.(Batisda
DAIC
MARCH 8, 2024
million grant awarded to Georgia Tech by the United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP) as part of the agency’s call for the development of less invasive treatment technologies for cardiovascular conditions associated with cardiomyopathy. Through a new four-year, $7.8
DAIC
MAY 6, 2024
We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Expert insights. Personalized for you.
52 
Let's personalize your content